At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 135 enrolled
Drug / intervention
Epinephrine Inhalation Solution +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Inhaled Beta-2 Agonist Versus Epinephrine For Treatment of Transient Tachypnea of Newborn
In Brief
A Phase 1 clinical trial evaluating Epinephrine Inhalation Solution, Salbutamol, and 1 other intervention for Transient Tachypnea of the Newborn. Completed, enrolled 135 participants.
Detailed Summary
Inhaled Beta-2 Agonist Versus Epinephrine For Treatment of Transient Tachypnea of Newborn: Randomized controlled trial to assess:
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTransient Tachypnea of the Newborn
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2014
Primary CompletionDec 2015
First PostedAug 2021
TodayJul 2026
First PostedAug 16, 2021
Enrollment StartFeb 1, 2014
Primary CompletionDec 31, 2015
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 4.9 years ago
Interventions
Epinephrine Inhalation Solutiondrug
Salbutamoldrug
Saline Inhalantsdrug